Began global shipments for Visium HD, a new
product that enables whole transcriptome spatial discovery at
single cell–scale resolution
PLEASANTON, Calif., March 26,
2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, announced today
the commercial availability of its Visium HD Spatial Gene
Expression product. This assay enables researchers to measure the
whole transcriptome from FFPE tissue sections at single cell-scale
resolution.
"Visium HD is a game-changer for spatial discovery research, and
our team couldn't be more proud and excited to get this
long-awaited product into the hands of our customers," said
Michael Schnall-Levin, Founding
Scientist and Chief Technology Officer at 10x Genomics. "This is
the most requested product in our history, and I can't think of a
better example of how 10x listens to our customers and takes on the
hardest development challenges to have the biggest impact on
scientific research. We're confident researchers will agree Visium
HD was well worth the wait."
Combining the power of whole transcriptome spatial discovery
with histological insights, Visium HD enables comprehensive
characterization of FFPE tissue samples. Visium HD offers:
- Whole transcriptome spatial discovery power at single cell
scale: Use next-generation slide architecture, which provides
transcript data in 2 x 2 µm barcoded squares without gaps, to
resolve fine anatomical structures and map cell types and states at
single cell-scale resolution.
- Best-in-class sequencing-based spatial transcriptomics
data: Map gene expression with precision and high confidence
using a simple and robust workflow exclusively available on Visium
CytAssist.
- FFPE compatibility: Generate powerful data from human or
mouse FFPE samples, including archived blocks or pre-sectioned
slides, using a universal sample preparation protocol.
- Enhanced histology: Integrate H&E or IF images with
high-resolution spatial transcriptomics from the same tissue
section.
- Easy-to-use analysis and visualization tools: Seamlessly
combine histological and gene expression data using updated
versions of Space Ranger and Loupe Browser to enable intuitive data
exploration and accelerate discovery.
The company will host a webinar to introduce Visium HD on
April 2, 2024 at 12 PM E.T. Register here.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with
us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, capabilities, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-commercially-launches-visium-hd-spatial-gene-expression-assay-302099533.html
SOURCE 10x Genomics, Inc